Skip to Main Content

Paper Details

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Prostate
7
2021
Author NameAffiliation
Lawrence D TrueUniversity of Washington
Jonathan L WrightUniversity of Washington
Evan Y YuUniversity of Washington
Evan Y YuClinical Research Division, Fred Hutchinson Cancer Research Center
Bruce MontgomeryUniversity of Washington
Bruce MontgomeryGeriatric Research Education and Clinical Care
Elahe A MostaghelUniversity of Washington
Elahe A MostaghelClinical Research Division, Fred Hutchinson Cancer Research Center
Elahe A MostaghelGeriatric Research Education and Clinical Care
Daniel W LinUniversity of Washington
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
Peter S NelsonUniversity of Washington
Peter S NelsonFred Hutchinson Cancer Research Center
  • 1 - 14

Datasets

Release 1.2